Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
De-escalation Strategy of Tyrosine Kinase Inhibitors Before Treatment Discontinuation in Patients With Chronic Myeloid Leukemia
NCT07839988Phase 4Not yet recruiting
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Sep 2026
- Primary completion
- Jul 2030
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in chronic myeloid leukemia (CML) (2 arms), sponsored by Nanfang Hospital, Southern Medical University. Primary endpoint: Molecular Relapse-Free Survival at 2 years. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT07839988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07839988.